Abstract
Background and objectives Most cancers appear with reduced frequency in Parkinson’s disease (PD), but the prevalence of melanoma and brain cancers are often reported to be increased. Shared genetic architecture and causal relationships to explain these associations have not been fully explored.
Methods Linkage disequilibrium score regression (LDSC) was applied for five cancer studies with available genome-wide association studies (GWAS) summary statistics to examine genetic correlations with PD. Additionally, we used GWAS summary statistics of 15 different types of cancers as exposures and two-sample Mendelian randomization to study the causal relationship with PD (outcome).
Results LDSC analysis revealed a potential genetic correlation between PD and melanoma, breast cancer and prostate cancer. There was no evidence to support a causal relationship between the studied cancers and PD.
Conclusions Our results suggest shared genetic architecture between PD and melanoma, breast, and prostate cancers, but no obvious causal relationship between cancers and PD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was performed using avaliable summary statstics from genome wide associational studies. No additional ethical approval is needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding agencies: This study was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada.
Relevant conflicts of interest/financial disclosures: ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali and Deerfield. AJN received grants from the Barts Charity, Parkinson’s UK and Aligning Science Across Parkinson’s; and honoraria from Britannia, BIAL, AbbVie, Global Kinetics Corporation, Profile, Biogen, and Roche. The rest of the authors have nothing to report.
Data Availability
All code used in the current study is available at our GitHub at https://github.com/gan-orlab/MR_Cancers-PD
